2. Anti-infection Apoptosis NF-κB Immunology/Inflammation
  3. Influenza Virus Apoptosis NF-κB Interleukin Related NO Synthase Toll-like Receptor (TLR)
  4. IAV-IN-5

IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection.

For research use only. We do not sell to patients.

IAV-IN-5

IAV-IN-5 Chemical Structure

CAS No. : 3038861-11-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IAV-IN-5 Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection[1].

IC50 & Target[1]

NF-κB

 

IL-4

 

IL-6

 

TLR3

 

iNOS

 

In Vitro

IAV-IN-5 (compound 3h) (25-100 μM; 24 h post-infection) dose-dependently inhibits RIG-I protein expression and phosphorylated NF-κB levels in A/Weiss/43 (H1N1)-infected A549 cells, blocking activation of the NF-κB inflammatory signaling pathway[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IAV-IN-5 Related Antibodies

Western Blot Analysis[1]

Cell Line: A549 cells infected with A/Weiss/43 (H1N1)
Concentration: 25, 50, 100 μM
Incubation Time: 24 h post-infection
Result: Dose-dependently inhibited RIG-I protein expression compared to the virus control group.
Significantly reduced pNF-κB levels compared to the virus control group.
In Vivo

IAV-IN-5 (compound 3h) (25-100 mg/kg/d; i.g.; daily; 6 days) dose-dependently alleviates influenza A virus-induced pathology in BALB/c mice, with the 100 mg/kg/d dose achieving a 50.26% lung index inhibition rate, reducing viral load, suppressing inflammatory cytokine expression, and decreasing alveolar apoptosis[1].
IAV-IN-5 (100 mg/kg/d; i.g.; daily; 6 days) shows excellent in vivo safety in healthy BALB/c mice, with no observable organ toxicity or changes in blood or serum biochemical parameters[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 5 weeks old, 13-17 g, intranasal inoculation with A/Weiss/43 H1N1 virus)[1]
Dosage: 25 mg/kg/d; 50 mg/kg/d; 100 mg/kg/d
Administration: i.g.; daily; 6 days
Result: Alleviated virus-induced weight loss and improved mouse survival.
Reduced hemorrhagic lesions and edema; 100 mg/kg/d caused only mild edema, similar to oseltamivir.
Inhibited lung index by 23.76% (25 mg/kg/d), 38.24% (50 mg/kg/d), and 50.26% (100 mg/kg/d); high-dose inhibition exceeded oseltamivir.
Mitigated alveolar wall thickening, interstitial edema, and inflammatory infiltration; 100 mg/kg/d maintained intact alveolar structure comparable to oseltamivir.
Decreased influenza virus NP protein staining in lung tissue dose-dependently, with the weakest signal at 100 mg/kg/d.
Reduced mRNA levels of viral NP and M2 genes in lung tissue on days 2, 4, and 6 post-infection at all doses.
Downregulated mRNA expression of inflammatory factors (RIG-I, TLR3, IRF3, ASC, iNOS, IL-4, IL-6, IFN-α) in lung tissue on day 6 post-infection at all doses.
Diminished apoptotic cells in lung tissue dose-dependently; 100 mg/kg/d was comparable to oseltamivir.
Animal Model: BALB/c (female, 5 weeks old, 13-17 g)[1]
Dosage: 100 mg/kg/d
Administration: i.g.; daily; 6 days
Result: Showed no obvious pathological changes, tissue damage, cell degeneration/necrosis, or inflammatory cell infiltration.
Maintained routine blood parameters within normal physiological ranges.
Kept serum biochemical indices close to normal control levels.
Molecular Weight

381.49

Formula

C22H23NO3S
CAS No.
SMILES

O=S(C1=CC=C(C)C=C1)(N(C2=C(C)[C@@]3([H])CCCC([C@@]23[H])=O)C4=CC=CC=C4)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IAV-IN-5 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IAV-IN-53038861-11-6Influenza VirusApoptosisNF-κBInterleukin RelatedNO SynthaseToll-like Receptor (TLR)Nuclear factor-κBNuclear factor-kappaBILNitric oxide synthasesNOSapoptosisBALB/c miceA/Weiss/43 (H1N1)lung tissuesinfluenza A virusoxidative stresscytokine stormA549 cellsRIG-I proteinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IAV-IN-5
Cat. No.:
HY-183313
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.